Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.

Forty-nine patients with advanced breast cancer who had failed from first-line cyclophosphamide, methotrexate, and 5-fluorouracil (CMF regimen) chemot...
558KB Sizes 0 Downloads 0 Views
Download PDF

Recommend Documents

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer.
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.
Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group.
FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial.
oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial.
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.

Follow Us

Copyright © 2024 D.DOCKSCI.COM. All rights reserved. | Design by w3layouts